MA28094A1 - Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine - Google Patents

Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine

Info

Publication number
MA28094A1
MA28094A1 MA28935A MA28935A MA28094A1 MA 28094 A1 MA28094 A1 MA 28094A1 MA 28935 A MA28935 A MA 28935A MA 28935 A MA28935 A MA 28935A MA 28094 A1 MA28094 A1 MA 28094A1
Authority
MA
Morocco
Prior art keywords
transporter inhibitors
glycine transporter
bicyclic derivatives
bicyclic
derivatives
Prior art date
Application number
MA28935A
Other languages
English (en)
Inventor
John A Lowe
Stan Mchardy
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34465157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA28094A1 publication Critical patent/MA28094A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine La présente invention concerne une série d'amines [3.1.0] bicycliques substituées de formule I: dans laquelle A, B, D, Q, V, W, X, Y, Z, R2, R3, R4, R5, R14, R15, R30, o, p, s, t et q sont tels que définis dans le présent mémoire, leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques les contenant, et leur utilisation pour améliorer la cognition et pour le traitement des symptômes positifs et négatifs de la schizophrénie et d'autres psychoses chez des mammifères, y compris des êtres humains.
MA28935A 2003-10-14 2006-04-14 Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine MA28094A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51084603P 2003-10-14 2003-10-14

Publications (1)

Publication Number Publication Date
MA28094A1 true MA28094A1 (fr) 2006-08-01

Family

ID=34465157

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28935A MA28094A1 (fr) 2003-10-14 2006-04-14 Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine

Country Status (26)

Country Link
US (1) US7473787B2 (fr)
EP (1) EP1680124B1 (fr)
JP (2) JP4732354B2 (fr)
KR (1) KR20060095865A (fr)
CN (2) CN101838271A (fr)
AP (1) AP2006003592A0 (fr)
AU (1) AU2004281794B2 (fr)
BR (1) BRPI0415356A (fr)
CA (1) CA2542279C (fr)
CR (2) CR8333A (fr)
DK (1) DK1680124T3 (fr)
EA (1) EA009903B1 (fr)
EC (1) ECSP066504A (fr)
ES (1) ES2634841T3 (fr)
GE (1) GEP20104959B (fr)
IL (1) IL174299A (fr)
IS (1) IS8355A (fr)
MA (1) MA28094A1 (fr)
MX (1) MXPA06004279A (fr)
NO (1) NO337361B1 (fr)
NZ (1) NZ546012A (fr)
RS (1) RS20060190A (fr)
TN (1) TNSN06109A1 (fr)
UA (1) UA86037C2 (fr)
WO (1) WO2005037216A2 (fr)
ZA (1) ZA200602174B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101838271A (zh) * 2003-10-14 2010-09-22 辉瑞产品公司 作为甘氨酸转运蛋白抑制剂的二环[3.1.0]衍生物
GB0408772D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
GB0408774D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
JP2008503585A (ja) 2004-06-22 2008-02-07 シェーリング　コーポレイション カンナビノイドレセプターリガンド
BRPI0608148A2 (pt) * 2005-04-08 2009-11-10 Pfizer Prod Inc [3.1.01] heteroaril amidas bicìclicas como inibidores de transporte de glicina do tipo i,composição farmacêutica para tratamento de distúrbio e seu uso
US8067457B2 (en) 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053499A2 (fr) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Composés pouvant être employés en tant qu'antagonistes de ccr2
WO2007135527A2 (fr) * 2006-05-23 2007-11-29 Pfizer Products Inc. Composés de benzimidazolyle
WO2008065500A2 (fr) * 2006-11-30 2008-06-05 Pfizer Products Inc. Hétéroaryl amides comme inhibiteurs du transport de la glycine de type i
HRP20130097T1 (hr) * 2007-11-05 2013-02-28 Merck Patent Gmbh Derivati 7-azaindola kao selektivni inhibitori 11-beta-hidroksisteroidne dehidrogenaze tipa 1
US8211933B2 (en) * 2008-12-12 2012-07-03 Vanderbilt University 3.3.0 bicyclic GlyT1 inhibitors and methods of making and using same
WO2010078348A1 (fr) * 2008-12-29 2010-07-08 Vanderbilt University Inhibiteurs de glyt1 bicyclique et leurs procédés de production et d'utilisation
FR2944283B1 (fr) * 2009-04-14 2011-05-06 Sanofi Aventis Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
WO2010107115A1 (fr) 2009-03-19 2010-09-23 大正製薬株式会社 Inhibiteur de transporteur de glycine
US8729271B2 (en) 2010-09-17 2014-05-20 Taisho Pharmaceutical Co., Ltd Glycine transporter inhibiting substances
EP2621902B1 (fr) 2010-09-28 2017-04-12 Panacea Biotec Ltd Dérivés de 3-azabicyclo[3.1.0]hexane utiles pour le traitement de troubles du snc
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
CN103319645B (zh) * 2013-05-31 2016-08-10 南京洁雅新材料有限公司 一种水性金属保护剂及其生产工艺
ES2774923T3 (es) * 2014-04-28 2020-07-23 China Resources Pharmaceutical Holdings Company Ltd Derivados de isoquinolinsulfonilo como inhibidores de RHO quinasa
EP3350166A4 (fr) 2015-09-16 2019-05-01 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
WO2017049172A1 (fr) 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
CA2998493A1 (fr) 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du recepteur x farnesoide et leurs utilisations
EP3350164A4 (fr) * 2015-09-16 2019-03-27 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
UA129159C2 (uk) * 2019-05-01 2025-01-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх ТВЕРДІ ФОРМИ ІНГІБІТОРА GlyT1
TW202108559A (zh) 2019-05-31 2021-03-01 美商醫肯納腫瘤學公司 Tead抑制劑及其用途
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
BR112022026698A2 (pt) 2020-08-13 2023-02-23 Boehringer Ingelheim Int Tratamento da deficiência cognitiva associada à esquizofrenia
CA3195702A1 (fr) 2020-10-13 2022-04-21 Boehringer Ingelheim International Gmbh Procede de retraitement
TW202444703A (zh) 2021-09-14 2024-11-16 美商美國禮來大藥廠 Sstr4促效劑鹽
WO2024245077A1 (fr) * 2023-05-29 2024-12-05 武汉熙瑞医药科技有限公司 Dérivé de 3-aza-bicyclo[3.1.0]hexane, son procédé de préparation et son utilisation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT891332E (pt) * 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
SI1014966T1 (sl) * 1996-05-31 2006-10-31 Allelix Neuroscience Inc Zdravilo za zdravljenje nevroloskih in nevripsihiatricnih bolezni
US6897230B2 (en) * 2001-04-17 2005-05-24 Kyorin Pharmaceutical Co., Ltd. Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof
PL368919A1 (en) * 2001-10-22 2005-04-04 Pfizer Products Inc. 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
EP1442018A1 (fr) 2001-10-31 2004-08-04 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Nouveaux composes anticancereux
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
DE60230683D1 (de) * 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
WO2004018422A1 (fr) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
CA2522071A1 (fr) * 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Derives azabicyclo utiles comme antagonistes du recepteur muscarinique
CN101838271A (zh) * 2003-10-14 2010-09-22 辉瑞产品公司 作为甘氨酸转运蛋白抑制剂的二环[3.1.0]衍生物
KR20060096038A (ko) * 2003-10-16 2006-09-05 화이자 프로덕츠 인크. 3-아자비시클로〔3.1.0〕헥산 유도체의 제조법
EP1751115A4 (fr) 2004-05-23 2010-10-20 Gerard M Housey Modulateurs de theramuteine

Also Published As

Publication number Publication date
AU2004281794B2 (en) 2010-04-22
IS8355A (is) 2006-03-16
KR20060095865A (ko) 2006-09-04
NO20062193L (no) 2006-05-15
JP4732354B2 (ja) 2011-07-27
ES2634841T3 (es) 2017-09-29
IL174299A (en) 2011-12-29
IL174299A0 (en) 2006-08-01
WO2005037216A3 (fr) 2005-08-04
CR8333A (es) 2007-08-14
CA2542279A1 (fr) 2005-04-28
EA009903B1 (ru) 2008-04-28
CN101838271A (zh) 2010-09-22
DK1680124T3 (en) 2017-08-21
GEP20104959B (en) 2010-04-26
BRPI0415356A (pt) 2006-12-12
US7473787B2 (en) 2009-01-06
CN1867338A (zh) 2006-11-22
ZA200602174B (en) 2007-04-25
NO337361B1 (no) 2016-03-29
WO2005037216A2 (fr) 2005-04-28
UA86037C2 (ru) 2009-03-25
MXPA06004279A (es) 2006-06-28
AU2004281794A1 (en) 2005-04-28
US20050096375A1 (en) 2005-05-05
EP1680124B1 (fr) 2017-05-31
CA2542279C (fr) 2011-08-09
JP2007508374A (ja) 2007-04-05
EP1680124A4 (fr) 2009-05-13
EA200600513A1 (ru) 2006-08-25
CR20110095A (es) 2011-03-09
NZ546012A (en) 2009-12-24
TNSN06109A1 (fr) 2007-11-15
AP2006003592A0 (en) 2006-04-30
ECSP066504A (es) 2006-10-10
RS20060190A (sr) 2008-08-07
EP1680124A2 (fr) 2006-07-19
JP2011157358A (ja) 2011-08-18

Similar Documents

Publication Publication Date Title
MA28094A1 (fr) Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
TNSN07380A1 (fr) [3.1.0]heteroarylamides bicycliques servant d'inhibiteurs du transport de glycine de type 1
MA27568A1 (fr) Derives de pyrrolopyrimidine
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
ATE275559T1 (de) Aromatische amin-derivate verwendbar als pharmazeutische mittel
MA31373B1 (fr) Composes amino-heterocycliques
TN2010000175A1 (fr) Piperidino-dihydrothienopyrimidines substituees
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA27438A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
MA28747B1 (fr) Dérivés de pyridine
TNSN98045A1 (fr) Derives de nicotinamide nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
TNSN96172A1 (fr) Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
TNSN98053A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant.
MA29926B1 (fr) Derives de pyrazine
MA27775A1 (fr) Composes organiques
TNSN98083A1 (fr) Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA39043A1 (fr) Dérivés de purine substitués en positions 2 et 6, et leur utilisation dans le traitement des désordres prolifératifs
TNSN00235A1 (fr) Derives d'heterocyclo-alkylsulfonylpyrazole nouveaux, procede pour leur preparation et compositions les contenant